AptaBio receives Phase 2 topline data for APX — 115 in contrast — induced acute kidney injury trial
AptaBio received topline Phase 2 data for Isuzinaxib (APX-115) in contrast-induced acute kidney injury on Oct. 14, 2026. The study met its primary safety objective, with no clinically meaningful safety signals versus placebo in overall participants. Safety findings also held in the higher-risk subgroup with impaired ki